prikaz prve stranice dokumenta Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke
  Download
PDF 331.84 KB
Scientific paper - Original scientific paper
Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke
Journal of the Neurological Sciences, 343 (2014), 1-2; 30-35. https://doi.org/10.1016/j.jns.2014.04.039
Šupe, Svjetlana; Božina, Nada; Matijević, Vesna; Bazina, Antonela; Mišmaš, Antonija; Ljevak, Josip; Alvir, Domagoj; Habek, Mario; Poljaković, Zdravka

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Šupe, S., Božina, N., Matijević, V., Bazina, A., Mišmaš, A., Ljevak, J. ... Poljaković, Z. (2014). Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke. Journal of the Neurological Sciences, 343. (1-2), 30-35. doi: 10.1016/j.jns.2014.04.039

Šupe, Svjetlana, et al. "Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke." Journal of the Neurological Sciences, vol. 343, no. 1-2, 2014, pp. 30-35. https://doi.org/10.1016/j.jns.2014.04.039

Šupe, Svjetlana, Nada Božina, Vesna Matijević, Antonela Bazina, Antonija Mišmaš, Josip Ljevak, Domagoj Alvir, Mario Habek and Zdravka Poljaković. "Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke." Journal of the Neurological Sciences 343, no. 1-2 (2014): 30-35. https://doi.org/10.1016/j.jns.2014.04.039

Šupe, S., et al. (2014) 'Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke', Journal of the Neurological Sciences, 343(1-2), pp. 30-35. doi: 10.1016/j.jns.2014.04.039

Šupe S, Božina N, Matijević V, Bazina A, Mišmaš A, Ljevak J, and sur.. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke. Journal of the Neurological Sciences [Internet]. 2014 August 15 [cited 2024 April 28];343(1-2):30-35. doi: 10.1016/j.jns.2014.04.039

S. Šupe, et al., "Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke", Journal of the Neurological Sciences, vol. 343, no. 1-2, pp. 30-35, August 2014. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:948851. [Accessed: 28 April 2024]

Metadata
Title (english)Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke
AuthorSvjetlana Šupe
AuthorNada Božina
AuthorVesna Matijević
AuthorAntonela Bazina
AuthorAntonija Mišmaš
AuthorJosip Ljevak
AuthorDomagoj Alvir
AuthorMario Habek
AuthorZdravka Poljaković
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
BACKGROUND: Data on the prevalence of CYP2C9 and VKORC1 genes and their influence on anticoagulant effect and warfarin dose in stroke patients are scarce. The aim of this study was to determine the occurrence and significance of these gene polymorphisms and to establish pharmacogenetic algorithm to estimate the dose of introduction. Also, the goal was to determine tailored safety and intensity of anticoagulation response depending on the allelic variants and their impact on the clinical outcome in acute stroke patients in Croatia. ----- METHODS: A total of 106 consented acute stroke patients were tested for CYP2C9 2, 3 and VKORC1 1173C>T gene polymorphisms. We estimated the dose of introduction and monitored anticoagulant effect obtained by INR values, time to reach stable dose, stable maintenance dose, time spent within the therapeutic/supratherapeutic INR range, occurrence of dosage side effects and clinical outcome depending on genotypes. ----- RESULTS: We found that 83% of stroke patients in our study were carriers of multiple allelic variants. The predicted initial dose correlated with the stable warfarin maintenance dose (p=0.0311) and we correctly estimated the dose for 81.5% of 61.3% of study patients who required higher/lower doses than average. Warfarin dosage complications were slightly more frequent among the carriers of CYP2C9 2, 3 compared to the carriers of VKORC1 1173T alleles (68. 9% versus 62.5%), but their occurrence did not affect the final clinical outcome. ----- CONCLUSION: Our data indicated rapid and safe anticoagulation achieved by using pharmacogenetically-predicted warfarin dose in high-risk acute stroke patients without increasing the risk of warfarin dosage complications in an elderly population.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleJournal of the Neurological Sciences
Numberingvol. 343, no. 1-2, pp. 30-35
p-ISSN0022-510X
DOIhttps://doi.org/10.1016/j.jns.2014.04.039
URN:NBNurn:nbn:hr:105:948851
Publication2014-08-15
Document URLhttps://doi.org/10.1016/j.jns.2014.04.039
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 08:03:47